Mydecine’s Exclusive Dealer Identified as Licensed Psilocybin and MDMA Supplier in Canada Post published:February 8, 2022 Post category:Press Release
Mydecine Welcomes Dr. Victoria Hale as Newest Independent Board Member Post published:February 3, 2022 Post category:Press Release
Mydecine Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial Post published:February 1, 2022 Post category:Press Release
Mydecine Partners with Combat Stress to Treat Post-Traumatic Stress Disorder in Veterans Post published:January 24, 2022 Post category:Press Release
Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy to Patients under Health Canada’s Special Access Program Post published:January 18, 2022 Post category:Press Release
Mydecine to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic-Assisted Psychotherapy For Patients Post published:January 13, 2022 Post category:Press Release
Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds Post published:January 10, 2022 Post category:Press Release
Mydecine Innovations Group Engages JBN Partners, LLC for Marketing Services Post published:January 7, 2022 Post category:Press Release
Mydecine Signs LOI with Maya to Co-Develop a Novel Prescription Digital Therapeutic Platform Aiming to Further Increase Safety, Efficacy, and Accessibility of Psychedelic-Assisted Treatments Post published:December 22, 2021 Post category:Press Release
Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives Post published:December 9, 2021 Post category:Press Release